BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Kidney, Avian flu virus, Doxycycline, rs7903146, MYC, glucose metabolic process)
Bookmark Forward

QuickView for complement component C1q binding (biogroup)


Body Atlas

Most Correlated Tissues

No tissues found
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Hepatocellular dysplasia
  2. Immunoglobulin G4 deficiency
  3. Fibrosis of lung
  4. Disease due to Picornaviridae
  5. Peritoneal foreign body
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Brefeldin A
  2. N-nitrosopiperidine
  3. niguldipine
  4. 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone
  5. COOH-terminal signal transamidase
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. MIR380
  2. GHR
  3. CLN5
  4. AGL
  5. Mir292
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

  1. L1000 CMAP - Umbilical vein endothelial HUVEC cells treated with small molecule perturbagens
  2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
  3. Pancreatic islets from cadaveric donors treated with brefeldin A
  4. L1000 CMAP - Neuronal NEU cells treated with small molecule perturbagens
  5. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Identification of human host proteins contributing to H5N1 influenza virus propagation by membrane p…
  2. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, …
  3. Lack of immunoglobulins does not prevent C1q binding to RGC and does not alter the progression of ex…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (D…
  2. Efferocytosis and Genomic Polymorphism in Autoimmune Diseases
  3. A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With C…
  4. A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pan…
  5. Serum Level of Myokines and Protein Energy Wasting, Inflammation and Atherosclerosis in Hemodialysis…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.